Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration

Canadian Journal of Ophthalmology

Volumn 40, Issue 3, 2005, Pages 313-319

  Oliver Fernandez, Alejandro ^a,b   Bakal, Jeff ^b   Segal, Shaun ^b   Shah, Gaurav K ^c   Dugar, Ashish ^d   Sharma, Sanjay ^b  

^a INDIANA UNIVERSITY   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c WASHINGTON UNIVERSITY   (United States)

^d PFIZER INC   (United States)

Author keywords

Age factor; Choroidal neovascularization; Low vision; Macular degeneration; Pegaptanib; Treatment delays

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; MODEL; PERIMETRY; RETINA MACULA AGE RELATED DEGENERATION; RISK; SCANNING LASER OPHTHALMOSCOPY; SUBRETINAL NEOVASCULARIZATION; TIME; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 21744461121     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/S0008-4182(05)80074-2     Document Type: Article

References (22)

1. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001;108:697-704.
2. Armbrecht AM, Aspinall PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. Br J Ophthalmol 2004;88:1270-3.
3. Zaidi FH, Cheong-Leen R, Gair EJ, Weir R, Sharkawi E, Lee N, et al. The Amsler chart is of doubtful value in retinal screening for early laser therapy of subretinal membranes. The West London Survey. Eye 2004;18:503-8.
4. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 1994;112:500-9.
5. Rubin GS, Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity: results from the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Investigation - TAP report no. 4. Retina 2002;22:536-44.
6. Mackenzie PJ, Chang TS, Scott IU, Linder M, Hay D, Feuer WJ, et al. Assessment of vision-related function in patients with age-related macular degeneration. Ophthalmology 2002;109:720-9.
7. Clemons TF, Chew EY, Bressler SB, McBee W; Age-Related Eye Disease Study Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS report no. 10. Arch Ophthalmol 2003;121:211-7.
8. Childs AL; Submacular Surgery Trials Patient-Centered Outcomes Subcommittee for the Submacular Surgery Trials Pilot Study Investigators. Responsiveness of the SF-36 health survey to changes in visual acuity among patients with subfoveal choroidal neovascularization. Am J Ophthalmol 2004;137:373-5.
9. Sharma S, Brown GC, Brown MM, Shah GK, Snow K, Brown H, et al. Converting visual acuity to utilities. Can J Ophthalmol 2000;35:267-72.
10. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47-51.
11. Klein ML, Jorizzo PA, Watzke RC. Growth features of choroicial neovascular membranes in age-related macular degeneration. Ophthalmology 1989;96:1416-9.
12. Vander JF, Morgan CM, Schatz H. Growth rate of subretinal neovascularization in age-related macular degeneration. Ophthalmology 1989;96:1422-6.
13. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, et al; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003;110: 2372-83: discussion 2384-5.
14. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report no. 1 [published erratum appears in Arch Ophthalmol 2000;118: 488]. Arch Ophthalmol 1999;117:1329-45.
15. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220-31.
16. Gragoudas KS, Adamis AP, Cunningham KT Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351: 2805-16.
17. Fujii GY, de Juan E Jr, Humayun MS, Sunness JS, Chang TS, Rossi JV. Characteristics of visual loss by scanning laser ophthalmoscope microperimetry in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003;136:1067-78.
18. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, et al. Verteporfin therapy for subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion compositions impact on vision outcomes - TAP report no. 3. Arch Ophthalmol 2002;120:1443-54.
19. Hatch WV, Trope GE. Waiting times for eye surgery at a Toronto teaching hospital. Can J Ophthalmol 2004;39:31-7.
20. Goldberg LD. Clinical guidelines for the treatment of glaucoma. Manag Care 2002;11(11 Suppl):16-24.
21. NCQA adds four new measures to HEDIS 2005. Qual Lett Healthc Lead 2004;16(8):12-3.
22. Nast S, Richard SA, Martin DK. Ethical issues related to cardiac report cards. Can J Cardiol 2004;20:325-8.